Application and precautions of Eltrombopag/Eltrombopag in special groups (such as pregnant women and children)

Eltrombopag/ Eltrombopag is a drug used to treat idiopathic thrombocytopenic purpura (ITP). It improves patient symptoms bypromoting platelet production in the bone marrow to increase platelet count. However, using eltrombopag in special populations requires caution and following your doctor's recommendations and precautions.

Available data from the few published case reports and postmarketing experience with eltrombopag in pregnant women are insufficient to assess any drug-related risk of major birth defects, miscarriage, or adverse maternal-fetal outcomes. In animal reproductive and developmental toxicity studies, oral administration of eltrombopag to pregnant rats during organogenesis resulted in embryonic lethality and fetal weight loss at maternally toxic doses. Therefore, sexually active females of reproductive potential should use effective contraception (methods that result in a pregnancy rate of less than 1%) during treatment with eltrombopag and for at least 7 days after stopping treatment. Breastfeeding during treatment is not recommended due to the potential for serious adverse reactions in breastfed children. If possible, other treatments should be preferred to manage ITP.

The safety and efficacy of eltrombopag have been demonstrated in pediatric patients 1 year and older with persistent or chronic ITP and in pediatric patients 2 years and older with standard immunosuppressive therapy (IST) severe aplastic anemia (in combination with h-ATG and cyclosporine). The safety and effectiveness of ITP in pediatric patients younger than 1 year of age have not been established. Safety and efficacy have not been established in pediatric patients with chronic hepatitis C and refractory severe aplastic anemia-associated thrombocytopenia. Therefore, the risks and benefits of medications need to be carefully evaluated. When using eltrombopag in children, doctors usually determine the dose based on the patient's age, weight and clinical condition, and closely monitor the patient's platelet count and side effects.